Cardiol Therapeutics ($CRDL) just highlighted major 2025 progress in its Year-End Operations Update: https://finance.yahoo.com/sectors/healthcare/...19254.html
[color=rgb(93, 55, 230)]MAVERIC Phase III trial for recurrent pericarditis now >50% enrolled — full enrollment targeted for Q2 2026
Positive Phase II ARCHER results showed significant reduction in left ventricular mass
CRD-38 oral formulation advancing toward IND/Phase I
New U.S. patent allowance extending protection to 2040
Raised ~$31M in recent financings — now fully funded through MAVERIC completion and into Q4 2027[/color]
Canaccord Genuity recently reaffirmed Buy rating with $8.00 price target — that’s over 500% upside from current levels around $1.29–$1.40.
Late-stage biotech play targeting serious inflammatory heart diseases with strong clinical momentum and solid cash runway.
Who’s watching $CRDL as this Phase III trial advances? Drop if you’re bullish on this cardiac innovation story!
#CRDL #CardiolTherapeutics #Biotech #HeartDisease #Stocks